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Abstract In this study, using rat carrageenin-induced pleurisy,
we found that treatment of rats with either indomethacin or NS-
398 suppressed the pleurisy at 2 h but significantly exacerbated
this reaction at 48 h. Exacerbated inflammation was associated
with reduced prostaglandin D2 levels, decreased heat shock
factor 1 (HSF1) activation, reduced hsp72 expression and
increased activation of nuclear factor UB (NF-UB). Replacement
of cyclopentenone prostaglandins by treating rats with either
prostaglandin J2 or prostaglandin D2 reversed the exacerbating
effects of cyclooxygenase inhibitors leading to the resolution of
the reaction. In conclusion, we demonstrate that cyclopentenone
prostaglandins may act as anti-inflammatory mediators by
inducing in inflammatory cells HSF1-dependent hsp72 expres-
sion and NF-UB inhibition, two crucial events for the remission of
inflammation. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Carrageenin-induced pleurisy in rats is an experimental
model of acute in£ammation characterized by plasma extra-
vasation and migration of phagocytic cells. Polymorphonuclear
leukocytes are the predominant cell type up to 12 h, then they
are replaced by migrating mononuclear cells, which di¡eren-
tiate into macrophages and dominate the reaction up to res-
olution at 48 h [1,2]. These in£ammatory cells synthesize and
release a rather intricate cascade of mediators of in£ammation
among which prostaglandins (PGs) play a relevant role. PGs
are a family of signaling molecules synthesized from arachi-
donic acid by the enzyme cyclooxygenase (COX). COX occurs
in two isoforms, COX-1 and COX-2. Generally, COX-1 is
constitutively expressed in most tissues, where it modulates
physiological processes [3], while inducible COX-2 is consid-
ered a pro-in£ammatory enzyme and a chief target for the
treatment of in£ammatory disease [4]. However, it has re-
cently been shown that COX-2 may have anti-in£ammatory
properties. In fact, it has been found that in the early poly-
morphonuclear leukocytes-dominated phase of rat carragee-
nin-induced pleurisy COX-2 mainly catalyzes the synthesis
of pro-in£ammatory prostaglandins (in particular PGE2)
while in the late mononuclear cells-dominated stage of this
in£ammatory reaction COX-2 directs the synthesis of cyclo-
pentenone prostaglandins (cyPGs), suggesting a physiological
anti-in£ammatory role for these molecules in the resolution of
an in£ammatory reaction [5]. It has been hypothesized that
cyPGs exert anti-in£ammatory activity through the activation
of peroxisome proliferator-activated receptor-Q (PPAR-Q), a
nuclear receptor that interferes with the transcriptional activ-
ity of the transcription factor nuclear factor-UB (NF-UB) [6,7].
However, recent in vitro studies have shown that cyPGs are
able to inhibit the phosphorylation and prevent the degrada-
tion of the NF-UB inhibitor IUB-K in human cells expressing
very low levels of PPAR-Q [8].
Recent in vitro studies have shown that cyPGs in a non-
stressful situation selectively induce in mammalian cells the
expression of speci¢c heat shock genes [9]. Induction is medi-
ated by the activation and translocation to the nucleus of a
transregulatory protein, the heat shock transcription factor
(HSF), which binds to multiple arrays of heat shock elements
located in the promoter region of heat shock genes [10]. HSF
activation requires trimerization, acquisition of DNA binding
activity, localization to the nucleus, and inducible serine phos-
phorylation resulting in stress-induced transcription of heat
shock proteins (hsp) [11]. Heat shock proteins have been
known for several years to protect cells against a wide variety
of toxic conditions, including extreme temperatures, oxidative
stress and virus infection [12]. Moreover, we have recently
shown that HSF1 is activated in vivo in the late stage of rat
carrageenin pleurisy and drives the in£ammatory reaction to
the remission since its selective inhibition by double-stranded
oligodeoxynucleotide caused exacerbation of the pleurisy [13].
In the present study, we demonstrate that in rat carrageenin-
induced pleurisy cyPGs may act as endogenous anti-in£am-
matory mediators by activating the HSF1/hsp72 pathway and
inhibiting NF-UB activation in the cells collected from pleural
exudate at the late stage of the in£ammatory reaction. Fur-
thermore, we show that the exacerbated pleurisy, consequent
on the treatment of animals with indomethacin or NS-398, is
associated to a lack of activation of the HSF1/hsp72 pathway
as well as to a prolonged NF-UB activation.
2. Materials and methods
2.1. Animals
Male Wistar rats (Harlan) weighing 175^200 g were used in all
experiments. Animal care was in accordance with Italian and Euro-
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pean regulations on the protection of animals used for experimental
and other scienti¢c purposes.
2.2. Induction of pleurisy
Carrageenin pleurisy induction, measurement of pleural exudate
and in£ammatory cell collection were carried out as previously de-
scribed [13].
2.3. Treatments
In a ¢rst set of experiments, groups of rats were treated with 0.1,
1.0 or 10 mg/kg NS-398 (Cayman Chemical) or 0.3, 1.0 or 3.0 mg/kg
indomethacin (Sigma), both dissolved in polyethyleneglycol (Sigma)
and administered p.o. by gastric gavage (0.5 ml/rat) 1 h before carra-
geenin injection. Two hours after the induction of pleurisy pleural
exudates were collected and processed as described [13].
In a second set of experiments both NS-398 (1, 3 or 10 mg/kg) and
indomethacin (0.3, 1 or 3 mg/kg) were given p.o. 24 h after induction
of pleurisy and every 6 h thereafter. NS-398 was used at a wider
dosing range at 2 h than at 48 h since it was more anti-in£ammatory
early. Some groups of animals, treated with NS-398 (10 mg/kg) or
indomethacin (3 mg/kg) 24 h after carrageenin injection as previously
described, were also injected into the pleural cavity with PGJ2 or
PGD2 (Cayman Chemical) both given at 100 Wg/kg. In this set of
experiments animals were killed 48 h after induction of pleurisy and
pleural exudates were collected and processed as described [13]. In
each set of experiments the control group received only vehicle(s) by
the appropriate route of administration.
2.4. Assay for PGE2 and PGD2
PGE2 and PGD2 amounts in the supernatant of centrifuged exu-
date were measured by enzyme immunoassay (Cayman Chemical).
2.5. Preparation of cell extracts
All the extraction procedures were performed on ice with ice-cold
reagents. Cells were separated from the in£ammatory exudate by cen-
trifugation at 800Ug for 10 min at 4‡C. In£ammatory cell pellets were
washed twice in phosphate-bu¡ered saline (ICN Biomedicals) and
centrifuged at 800Ug for 5 min at 4‡C. Whole-cell extracts were
prepared by resuspending the pellet in one packed cell volume of a
high-salt extraction bu¡er and incubated on ice for 15 min. After
centrifugation at 13 000Ug at 4‡C for 5 min, the protein concentra-
tion in the supernatant was determined by the Bio-Rad protein assay
kit (Bio-Rad) and then it was aliquoted and stored at 380‡C. Nuclear
extracts were prepared as previously described [14]. Protein concen-
tration was determined by the Bio-Rad protein assay kit (Bio-Rad).
2.6. Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides containing the NF-UB recogni-
tion sequence (5P-GAT CGA GGG GAC TTT CCC TAG-3P) or
the idealized heat shock element (5P-CTA GAA GCT TCT AGA
AGC TTC TAG-3P) sequence [15^17] were end-labeled with Q-
[32P]ATP (ICN Biomedicals). Aliquots of nuclear extracts (15 Wg of
protein for each sample) were incubated for 30 min with radiolabeled
oligonucleotides (2.5^5.0U104 cpm) in 20 Wl reaction bu¡er contain-
ing 2 Wg poly dI-dC, 10 mM Tris^HCl (pH 7.5), 100 mM NaCl, 1 mM
ethylenediaminetetraacetic acid, 1 mM DL-dithiothreitol, 1 mg/ml bo-
vine serum albumin, 10% v/v glycerol. The speci¢city of the DNA/
protein binding was determined for NF-UB by competition reaction in
which a 50-fold molar excess of unlabeled wild-type, mutant or Sp-1
oligonucleotide was added to the binding reaction 10 min before ad-
dition of radiolabeled probe. In supershift assay, antibodies reactive
to p50, p65 or c-Rel proteins (Santa Cruz Biotechnology) were added
to the reaction mixture 30 min before the addition of radiolabeled
NF-UB probe. The speci¢city of the DNA/protein binding was deter-
mined for HSF1 by competition reaction in which a 50-fold molar
excess of unlabeled wild-type, mutant or Oct-1 oligonucleotide was
added to the binding reaction 10 min before addition of radiolabeled
probe. In supershift assay, antibodies reactive to HSF1 (StressGen) or
HSF2 (LabVision) proteins were added to the reaction mixture 30 min
before the addition of radiolabeled HSF1 probe. Protein^nucleic acid
complexes were resolved by electrophoresis on 4% non-denaturing
polyacrylamide gel in 0.5U Tris borate ethylenediaminetetraacetic
acid bu¡er at 150 V for 2 h at 4‡C. The gel was dried and autoradio-
graphed with an intensifying screen at 380‡C for 20 h. Subsequently,
the relative bands were quanti¢ed by densitometric scanning of the
X-ray ¢lms with a GS-700 Imaging Densitometer (Bio-Rad) and a
computer program (Molecular Analyst, IBM).
2.7. Immunoprecipitation and Western blot analysis
The levels of p50, p65 and HSF1 were quanti¢ed in nuclear ex-
tracts, while the level of hsp72 was quanti¢ed in whole-cell extracts,
by immunoprecipitation followed by Western blot analysis according
to the manufacturer’s instruction (Santa Cruz Biotechnology). Brie£y,
equivalent amounts of whole cell extracts (100 Wg for each sample)
were mixed with 40 Wl of protein A-Sepharose and 2 Wl of anti-p65
(sc-109, Santa Cruz Biotechnology), anti-p50 (sc-8414, Santa Cruz
Biotechnology), anti-HSF1 (SPA-901, StressGen), or anti-hsp72
(SPA-812, StressGen) which speci¢cally recognizes the inducible but
not the constitutive member of the hsp70 family polyclonal antibod-
ies, and left overnight at 4‡C with continuous shaking. Precipitated
immunocomplexes were electrophoresed, transferred onto nitrocellu-
lose membranes and then incubated with anti-p65, anti-p50 and anti-
hsp72 antibodies for 1 h at room temperature. Precipitated HSF1 was
incubated with an anti-phosphoserine mouse monoclonal antibody
(Sigma Chemicals) as previously described [18]. Recombinant human
HSF1 protein and recombinant human hsp72 protein (StressGen)
were used as positive controls. The membranes were then incubated
with anti-rabbit or anti-mouse immunoglobulins coupled to peroxi-
dase. The immunocomplexes were visualized by the ECL chemilumi-
nescence method (Amersham). Subsequently, the relative expression
of the proteins was quanti¢ed by densitometric scanning of the X-ray
¢lms with a GS-700 Imaging Densitometer (Bio-Rad) and a computer
program (Molecular Analyst, IBM). L-Actin (Sigma) Western blot
analysis was performed to ensure equal sample loading.
2.8. Statistics
Data are expressed as mean þ S.E.M. for n rats. Statistical analysis
was done using an analysis of variance followed by a Bonferroni
Table 1
E¡ect of COX inhibitors on rat carrageenin-induced pleurisy
Treatment
(mg/kg/p.o.)


















None 422 þ 25 3122 þ 224 0.48 þ 0.03 10.4 þ 0.5 10 1444 þ 95 ND 0.25 þ 0.04 33.1 þ 5.8 10
Indomethacin
0.3 243 þ 39*** 2253 þ 166*** 0.26 þ 0.02*** 7.7 þ 0.5** 6 978 þ 48*** ND 0.26 þ 0.04 33.9 þ 4.3 7
1 190 þ 29*** 1340 þ 80*** 0.22 þ 0.05*** 4.9 þ 0.5*** 7 455 þ 22*** ND 0.32 þ 0.05 47.8 þ 3.1 8
3 ND 424 þ 73*** 0.12 þ 0.02*** 3.0 þ 0.4*** 7 156 þ 09*** ND 1.52 þ 0.10*** 81.2 þ 4.2*** 7
NS-398
0.1 198 þ 26*** 2012 þ 115*** 0.34 þ 0.02* 7.1 þ 0.5*** 6 NT NT NT NT ^
1 165 þ 32*** 1154 þ 101*** 0.22 þ 0.03*** 4.1 þ 0.2*** 7 815 þ 69*** ND 0.28 þ 0.03 41.5 þ 1.7 7
3 NT NT NT NT ^ 389 þ 56*** ND 0.50 þ 0.03*** 67.2 þ 2.5*** 8
10 ND 385 þ 74*** 0.18 þ 0.03*** 3.2 þ 0.1*** 7 ND ND 1.26 þ 0.10*** 83.5 þ 6.3*** 7
Each value represents the mean þ S.E.M. of n animals. *P6 0.05, **P6 0.01, ***P6 0.001 vs. control group. ND = not detectable; NT = dose
not tested.
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multiple comparison test. The level of statistically signi¢cant di¡er-
ence was de¢ned as P6 0.05.
3. Results
3.1. E¡ect of COX inhibitors on carrageenin pleurisy
We performed a series of experiments by treating rats with
indomethacin and NS-398 according to the protocol carried
out by Gilroy et al. [5] and obtained similar results (Table 1).
Thus, we found that the pleural exudates of control rats, 2 h
after carrageenin injection, contained small amounts of PGD2
compared to PGE2. These amounts were dose-dependently
and signi¢cantly reduced by either indomethacin or NS-398.
Conversely, in control rats at 48 h, the amounts of PGD2 was
increased by about 3.5 times, while PGE2 was undetectable.
Both indomethacin and NS-398 dose-dependently and signi¢-
cantly reduced PGD2 levels in the 48 h exudates. We also
observed that COX inhibitors suppressed exudate formation
and cell migration at 2 h and increased them at 48 h. On no
occasion did treatment with COX inhibitors modify the di¡er-
ential cell count (s 90% polymorphonuclear leukocytes at 2 h
and s 70% mononuclear cells at 48 h). Moreover, as shown
by Gilroy et al. [5], we found that injection of PGJ2 (100 Wg/
kg) into the pleural cavity of rats, 24 h after carrageenin
challenge, inhibited both exudate volume and cell migration
by about 50% (Fig. 1). Furthermore, when PGJ2 (100 Wg/kg)
was injected in rats previously treated with indomethacin (3.0
mg/kg) or with NS-398 (10 mg/kg), a complete reversion of
the exacerbating e¡ects of these COX inhibitors was observed.
Similar results were obtained by using PGD2 (data not
shown).
3.2. NF-UB and HSF1 activation and hsp72 expression in rat
carrageenin pleurisy
As shown in Fig. 2A, a retarded band of NF-UB/DNA
complex was faintly detected in normal rats (i.e. animals
which did not receive carrageenin or drugs). This band was
greatly increased 2 h after carrageenin injection and de-
creased, but was still clearly detectable, 48 h later. The com-
position of the NF-UB complex activated by carrageenin was
determined by competition and supershift experiments (Fig.
2A). The speci¢city of the NF-UB/DNA binding complex was
demonstrated by the complete displacement of NF-UB/DNA
binding in the presence of a 50-fold molar excess of unlabeled
NF-UB probe in the competition reaction. In contrast, a 50-
fold molar excess of unlabeled mutated NF-UB probe or Sp-1
oligonucleotide had no e¡ect on this DNA binding activity.
The composition of the NF-UB complex activated by carra-
geenin was determined by using speci¢c antibodies against
p50, p65 or p50+p65 and c-Rel subunits of NF-UB proteins.
Addition of either anti-p50 or anti-p65 or anti-p50+anti-p65,
but not anti-c-Rel, to the binding reaction resulted in a
marked reduction of NF-UB band intensity and, in addition,
the p50 antibody caused mobility retardation. EMSA per-
formed on nuclear extracts from pleural cells exhibited a pro-
¢le of HSF1/DNA binding activity opposite to that observed
for NF-UB/DNA binding activity. Thus, HSF1/DNA binding
activity was virtually undetectable in pleural cells from normal
rats or from carrageenin-treated rats 2 h after injection,
whereas maximum HSF1 activation was detected 48 h later
(Fig. 2B). The enhanced activation of HSF1 observed at 48 h
was associated with increased expression of hsp72 compared
to that observed in extracts from cells collected from either
normal rats or carrageenin-treated rats 2 h after injection
(Fig. 2C). Equal loading was con¢rmed by L-actin staining
(data not shown).
In order to con¢rm the speci¢city of the HSF1/DNA com-
Fig. 1. E¡ects of PGJ2, indomethacin and NS-398, given alone or
in combination, on exudate volume (empty columns) and cell in¢l-
tration (¢lled columns) evaluated at 48 h. Each column represents
the mean þ S.E.M. of 7^10 rats. *P6 0.05, **P6 0.01, ***P6 0.001
vs. control group; ‡‡‡P6 0.001 vs. indomethacin group;
P6 0.001 vs. NS-398 group.
Fig. 2. Analysis of NF-UB/DNA binding activity (A), HSF1/DNA
binding activity (B) and of hsp72 protein expression (C) performed
on pleural cells collected from normal rats (N) or from carrageenin-
treated rats 2 h and 48 h after the challenge. A: Competition reac-
tion in which nuclear extracts of in£ammatory cells collected at 2 h
were incubated with radiolabeled NF-UB probe in the absence or
presence of identical but unlabeled oligonucleotide wild-type (W.T.
50U), mutated non-functional UB probe (Mut. 50U) or unlabeled
oligonucleotide containing the consensus sequence for Sp-1 (Sp-1
50U) and supershift experiment in which the same nuclear extracts
were incubated with antibodies against p50, p65, p50+p65 or c-Rel
30 min before incubation with radiolabeled NF-UB probe. B: Com-
petition reaction in which nuclear extracts of in£ammatory cells col-
lected at 48 h were incubated with radiolabeled HSF probe in the
absence or presence of identical but unlabeled oligonucleotide wild-
type (W.T. 50U), mutated non-functional HSF probe (Mut. 50U)
or unlabeled oligonucleotide containing the consensus sequence for
Oct-1 (Oct-1 50U) and a supershift experiment in which the same
nuclear extracts were incubated with antibodies against HSF1 or
HSF2 30 min before incubation with radiolabeled HSF probe.
C: hsp72 evaluated by Western blot analysis. Recombinant human
hsp72 was used as a positive control (PC). Data illustrated in each
panel are from a single experiment and are representative of three
separate experiments.
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plex activated by carrageenin we performed competition and
supershift experiments (Fig. 2B). The speci¢city of the HSF1/
DNA binding complex was demonstrated by the complete
displacement of HSF1/DNA binding in the presence of a
50-fold molar excess of unlabeled HSF probe in the competi-
tion reaction. In contrast, a 50-fold molar excess of unlabeled
mutated HSF probe or Oct-1 oligonucleotide had no e¡ect on
this DNA binding activity. Furthermore, to establish which
member of the HSF family was activated by carrageenin,
nuclear cell extracts were preincubated with antibodies speci¢c
for either HSF1 or HSF2 and analyzed by EMSA. Addition
of anti-HSF1 but not anti-HSF2 to the binding reaction re-
sulted in both marked reduction of intensity and mobility
retardation of the HSF band, thus indicating that carrageenin
induces HSF1/DNA binding activity (Fig. 2B).
3.3. E¡ect of COX inhibitors on p50 and p65 nuclear
levels at 2 h
In control animals (carrageenin alone), 2 h after carrageenin
injection, high levels of both p50 and p65 NF-UB subunits
were detected by immunoblotting analysis as compared to
normal rats (Fig. 3A,C). As revealed by relative densitometric
analysis (Fig. 3B,D), treatment of rats with indomethacin (3.0
mg/kg) or NS-398 (10 mg/kg) signi¢cantly inhibited both p50
(by 74 and 81%, respectively) and p65 (by 57 and 59%, re-
spectively) nuclear levels.
3.4. E¡ect of COX inhibitors on HSF1 activation and hsp72
expression at 2 h
In control animals (carrageenin alone) 2 h after carrageenin
injection, neither activation of HSF1 nor increased expression
of hsp72 was detected by immunoblotting analysis as com-
pared to normal rats (Fig. 4A,B). In contrast, both non-ster-
oidal anti-in£ammatory drugs (NSAIDs) induced an incom-
plete stress response increasing the constitutively
phosphorylated and transcriptionally inert isoform of HSF1,
but not hsp72 protein expression as demonstrated by immu-
Fig. 3. E¡ects of indomethacin (Indo; 3 mg/kg) and NS-398 (10
mg/kg) on p50 and p65 nuclear translocation in in£ammatory cells,
collected 2 h after carrageenin injection, evaluated by Western blot
(A,C) and densitometric analysis (B,D). N = cells from normal rats.
Each immunoblot is from a single experiment and is representative
of three separate experiments. Densitometry results are expressed as
mean þ S.E.M. of three separate experiments. *P6 0.05, **P6 0.01
vs. control group (C). Fig. 4. E¡ects of indomethacin (Indo; 3 mg/kg) and NS-398
(10 mg/kg) on HSF1 activation and hsp72 protein expression in in-
£ammatory cells collected 2 h after carrageenin challenge. A: Western
blot of HSF1 activation. Recombinant human HSF1 protein was
used as a positive control (PC). HSF1 was immunoprecipitated by
anti-HSF1 antibody and analyzed by immunoblotting using an anti-
phosphoserine monoclonal antibody. The antibody used clearly de-
tects the transcriptionally active, hyperphosphorylated form of
HSF1 (S), as well as the inactive faster migrating isoform (F). B,C:
hsp72 protein expression evaluated respectively by Western blot and
densitometric analysis. N = cells from normal rats; C = cells from
control rats. Each immunoblot is from a single experiment and is
representative of three separate experiments. Densitometry results
are expressed as mean þ S.E.M. of three separate experiments.
Fig. 5. E¡ects of PGJ2, indomethacin and NS-398, given alone or in combination, on p50 and p65 nuclear translocation in in£ammatory cells,
collected 48 h after challenge, evaluated by Western blot (A,C) and densitometric analysis (B,D). Each immunoblot is from a single experiment
and is representative of three separate experiments. Densitometry results are expressed as mean þ S.E.M. of three separate experiments.
*P6 0.05, **P6 0.01 vs. control group; ‡P6 0.05, ‡‡P6 0.01 vs. indomethacin group; P6 0.01 vs. NS-398 group.
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noprecipitation and Western blotting analysis (Fig. 4A,B).
Equal loading was con¢rmed by L-actin staining (data not
shown).
3.5. E¡ect of cyPGs and COX inhibitors on p50 and p65
nuclear levels at 48 h
As shown in Fig. 5A,C, low levels of both p50 and p65 NF-
UB subunits were detected in nuclear extracts from control
animals as compared to those measured at 2 h (Fig. 3A,C).
Treatment of rats with PGJ2 (100 Wg/kg) signi¢cantly de-
creased both p50 and p65 nuclear levels by about 50%. In
contrast, indomethacin and NS-398 increased both p50 and
p65 band intensity by about 100% as compared to that of the
control group. Coinjection of PGJ2 with indomethacin or NS-
398 almost completely reversed the NSAID-induced activa-
tion of p50 and p65 nuclear translocation. Similar results
were also obtained with PGD2 (data not shown).
3.6. E¡ect of cyPGs and COX inhibitors on HSF1 activation
and hsp72 expression at 48 h
As shown in Fig. 6A,B, cells collected from control animals
showed the formation of the hyperphosphorylated higher mo-
lecular weight isoform of HSF1, and a signi¢cant increase of
hsp72 protein expression as compared to cells collected at 2 h
(Fig. 4A,B). Treatment of rats with PGJ2 (100 Wg/kg) only
slightly modi¢ed HSF1 and hsp72 protein expression as com-
pared to the control group. In contrast, indomethacin (3.0
mg/kg) and NS-398 (10 mg/kg) induced an incomplete stress
response increasing the band intensity of the constitutively
phosphorylated, fast migrating HSF1 isoform but not hsp72
protein expression, which, instead, was signi¢cantly reduced
by 65% and by 63% respectively, as compared to the control
group. This e¡ect was due to incomplete phosphorylation of
HSF1 induced by the two COX inhibitors [23], resulting in a
reduction of the transcriptionally active, hyperphosphorylated
HSF1 isoform and, consequently, of hsp72 protein expression.
Coinjection of PGJ2 with indomethacin or NS-398 almost
completely reversed the NSAID-induced e¡ect on HSF1 acti-
vation and hsp72 expression (Fig. 6A,B). Equal loading was
con¢rmed by L-actin staining (data not shown). Similar results
were also obtained with PGD2 (data not shown).
4. Discussion
We have recently shown that the inhibition of HSF1 acti-
vation reduced hsp72 expression and exacerbated carrageenin-
induced pleurisy, suggesting a relevant role for the HSF1/
hsp72 pathway as an endogenous anti-in£ammatory system
[13]. In this study we demonstrate that the HSF1/hsp72 path-
way is triggered by cyPGs and protects the organism from the
deleterious e¡ect of protracted activation of the in£ammatory
response. In fact, in rat carrageenin-induced pleurisy, the
pleural exudate of the early phase (2 h) contained low
amounts of PGD2 compared to PGE2 amounts (this paper
and [5]) and the in£ammatory cells showed constitutive levels
of both HSF1 and hsp72 and activation of NF-UB. However,
in the exudate collected at the resolution phase (48 h), PGD2
levels were increased by about 3.5-fold whereas PGE2 was
undetectable (this paper and [5]), and the cells showed activa-
tion of HSF1, increased expression of hsp72 and inhibition of
NF-UB. Treatment of rats with both the COX-2 selective in-
hibitor NS-398 and the dual COX-1/COX-2 inhibitor indome-
thacin suppressed the pleurisy at 2 h, but signi¢cantly exacer-
bated it at 48 h con¢rming previous ¢ndings by Gilroy et al.
[5]. Exacerbated reaction was associated with reduced PGD2
levels, decreased HSF1-induced hsp72 expression and, more
interestingly, increased NF-UB activation. Replacement of
cyPGs by treating rats with PGJ2 or PGD2 reversed the ex-
acerbating e¡ects of COX inhibitors leading to resolution of
in£ammation. cyPGs are a class of pharmacologically active
compounds, derivatives of PGD2, with intriguing properties.
In fact, they are characterized by the ability to activate the
inducible phosphorylated form of HSF1, which in turn acti-
vates hsp72 synthesis for extended periods (12^24 h) [9,10].
Inducible phosphorylation appears to be essential for tran-
scriptional activation since chemicals such as salicylates and
the NSAIDs aspirin and indomethacin cause HSF trimeriza-
tion, nuclear translocation and binding to the heat shock el-
ement of the endogenous hsp70 gene. However, they are un-
able to activate HSF phosphorylation, thus inducing a
transcriptionally inert DNA binding trimeric state, which is
unable to trigger the expression of hsp genes [11,19]. Cyclo-
pentenone prostaglandins have also been shown to inhibit the
activation of NF-UB [20,21], an inducible transcription factor
responsible for the early in£ammatory response and activation
of the immune system [22,23]. We have recently demonstrated
that one of the earliest molecular event following challenge of
rats with carrageenin is the activation of NF-UB which peaks
at 24 h and decreases along with the resolution of the in£am-
matory reaction [24]. Herein, our results suggest di¡erent roles
for HSF1 and NF-UB in the gene reprogramming during in-
£ammation. In fact, the present study demonstrates that in
the early phase of in£ammation, when polymorphonuclear
Fig. 6. E¡ects of PGJ2, indomethacin and NS-398 given alone or in
combination on HSF1 activation and hsp72 protein expression in in-
£ammatory cells collected 24 h after carrageenin challenge.
A: Western blot of HSF1 activation. HSF1 was immunoprecipitated
by anti-HSF1 antibody and analyzed by immunoblotting using an
anti-phosphoserine monoclonal antibody. The antibody clearly detects
the transcriptionally active, hyperphosphorylated form of HSF1 (S)
as well as the inactive faster migrating HSF1 isoform (F). B,C:
hsp72 protein expression evaluated respectively by Western blot and
densitometric analysis. Each immunoblot is from a single experi-
ment and is representative of three separate experiments. Densitom-
etry results are expressed as mean þ S.E.M. of three separate experi-
ments. ***P6 0.001 vs. control group; ‡‡‡P6 0.001 vs.
indomethacin group; P6 0.01 vs. NS-398 group.
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cells dominate, NF-UB plays a relevant role in pro-in£amma-
tory gene programming whereas, in the late, mononuclear
cells-dominated phase it is essentially HSF1 that drives the
reaction to resolution by selectively inducing the expression
of protective hsp. Thus it is possible to hypothesize that
cyPGs, synthesized in large quantities by COX-2 during the
late phase of carrageenin-induced pleurisy, drive the in£am-
mation to resolution acting through a double mechanism. On
the one hand cyPGs activate HSF1, resulting in increased
expression of cytoprotective hsp72 synthesis, and on the other
hand, they directly inhibit NF-UB activation resulting in re-
pression of pro-in£ammatory gene transcription. This dual
action of cyPGs suggests that potential novel therapeutic
strategies may rely upon the simultaneous activation of cyto-
protective genes and downregulation of in£ammatory genes,
uncovering a new scenario in which the cytoprotective e¡ect
of the heat shock response is ampli¢ed by rendering the cells
unresponsive to pro-in£ammatory signals. Another interesting
issue raised by our study is the dual e¡ect exhibited by indo-
methacin and by the selective COX-2 inhibitor NS-398 to-
wards NF-UB activation at the di¡erent phase of the in£am-
matory reaction. In fact, when these drugs were administered
to rats at the early phase of carrageenin pleurisy they exhib-
ited the expected anti-in£ammatory e¡ects and signi¢cantly
reduced NF-UB activation. However, when these agents
were administered to rats 24 h after carrageenin injection
the pleurisy was exacerbated, as shown by Gilroy et al. [5].
Moreover, in human cells, salicylate as well as other NSAIDs
were found to induce HSF1 activation which was not associ-
ated with an increased transcription of heat shock genes
[18,25]. In fact, also in our experimental model, both NSAIDs
used, irrespective of their selectivity towards COX isoforms,
triggered only an incomplete activation of HSF1, not accom-
panied by hyperphosphorylation, and thus transcriptionally
inert where expression of hsp72 was not detected. In conclu-
sion, this study shows that cyPGs may act as anti-in£amma-
tory mediators by inducing the HSF1/hsp72 pathway and by
inhibiting NF-UB activation. Furthermore, we suggest that the
use of agents able to trigger simultaneously the activation of
HSF1, which dictates the synthesis of protective chaperones,
and the inhibition of NF-UB, which starts the synthesis of
relevant pro-in£ammatory mediators, may represent a novel
therapeutic approach in the treatment of in£ammatory dis-
eases.
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